Many hands go into developing a new drug and it is over the course of several years. As a result, data winds up getting lost or work is duplicated.

For pharmaceuticals and CROs, internal processes can be a challenge with information scattered among various divisions each with separate tracking systems. Developing a new drug and submitting to the FDA is like navigating through a maze of complex processes. In order to reduce risk, one cohesive system needs to be implemented.

The use of many tools leads to a fragmented system.

Symptoms of a fragmented system include difficulty in identifying the resource availability, missed deadlines, work duplication, lack of dynamic tools that inter-operate across divisions, non-collaborative workforce. Fragmentation leads to mismanagement. Mismanagement leads to project failure. Project failure leads to loss of revenue. No one wants that! Something needs to connect the internal and external processes to bring order to all this chaos, to bridge gaps between divisions, partners and organizations.

Higher visibility of real-time status reports among teams will aid in lessening the probability of data loss. If teams can see what each member is doing it there will be less confusion, more confidence and a stronger support system. Clear handoffs among team members and other teams will also eliminate the risk of data loss. The transition of work ownership needs to be seamless to lower risk of data redundancy or duplication of work.

Overall, in the next couple of years, pharmaceuticals and CROs will need to figure out how to consolidate work efforts, track work with fewer tools, and share more with other downstream teams.

Contact us to learn more about how consolidating your work management tools can benefit your organization